Drug Delivery Designed for Daily Life

An innovative approach to a proven PAH therapy

Treprostinil is an established therapy for pulmonary arterial hypertension (PAH), but current delivery options can create a significant treatment burden. Corsair is developing an innovative transdermal approach intended to make treprostinil delivery simpler, more consistent, and practical for patients.

Advancing once-daily transdermal treprostinil delivery

TRX-248 Transdermal System is Corsair’s investigational treprostinil prodrug patch being developed for PAH. The once-daily, needle-free transdermal system is designed to provide steady and continuous treprostinil exposure.
A detailed view showing a woman gently peeling or pressing a protective, textured oval adhesive shield onto her arm to secure a medical patch or continuous glucose monitor.
A dedicated researcher with curly dark hair feels completely absorbed and inspired while peer into a laboratory microscope.

Transdermal expertise from development to commercialization

Corsair Pharma is led by a team with deep experience in transdermal drug delivery, pharmaceutical development, and commercialization. The company is applying that expertise to develop delivery solutions intended to reduce treatment burden and expand the practical use of proven therapies.